Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CollPlant Biotechnologies Ltd (CLGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 6-K Quarterly results
08/24/2023 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million ● Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement ● Entered into collaboration with Stratasys, a world-leading 3D printing company, with initial focus on the development of a bioprinting solution for the fabrication of CollPlant’ s regenerative breast implants ● Readying breast implant study in large animals for initiation by year end ● Continued positive sales trajectory for 3D bioinks ● Cash and cash equivalents totaled $22.3 million as of June 30, 2023; cash runway extended with addition...",
"COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2023"
07/18/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER"
06/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Notice and Proxy Statement with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders",
"Proxy Card for holders of ordinary shares with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders"
05/24/2023 6-K Quarterly results
Docs: "CURRENT REPORT",
"CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update ● Strong positive sales trajectory for rhCollagen based products ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant’ s recombinant human Collagen ● Readying sites to begin large-animal study planned in the second half of 2023 to advance 3D bioprinted regenerative breast implant program ● Conference call to be held on May 24, 2023 at 10:00 am U.S. ET; Dial-in information herein Rehovot, Israel, May 24, 2023 – CollPlant Biotechnologies , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue rege..."
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs"
03/29/2023 6-K Quarterly results
01/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Strategy"
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives"
01/03/2023 6-K Quarterly results
12/01/2022 6-K Quarterly results
11/17/2022 6-K Quarterly results
11/15/2022 6-K Quarterly results
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"About CollPlant"
08/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CORPORATE PRESENTATION"
08/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results · Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing · Company’ s 3D bioprinted regenerative breast implant program remains on track to conclude large animal study in Q4 · Development of aseptic process for the production of sterile rhCollagen anticipated to be completed in Q4 · Strong balance sheet with cash and cash equivalents of $36M as of June 30, 2022 Rehovot, Israel August 25, 2022 -- CollPlant Biotechnologies , a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second ...",
"COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2022"
06/29/2022 6-K Quarterly results
05/26/2022 6-K Quarterly results
05/02/2022 6-K Quarterly results
04/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CORPORATE PRESENTATION"
03/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Notice and Proxy Statement with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders",
"Proxy Card for holders of ordinary shares with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders"
03/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF THE FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results"
02/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CollPlant and CELLINK will explore the use of CELLINK's next-generation high throughput extrusion bioprinters for the future commercial production of CollPlant's regenerative breast implants, addressing a $2.8 Bn market CELLINK, Gothenburg, Sweden and CollPlant, Rehovot, Israel, February 16, 2022 -- Today, CELLINK, a BICO Group company and a global leader in developing 3D bioprinting technologies which is expected to bridge the current gap and allow unlimited supply of life saving organs and CollPlant Biotechnologies a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced they have signed a collaboration agreement. Under this collaboration, CELLINK’ s high-throughput, multi-material extrusion b..."
01/05/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Dea r Sha r e holder s, 2021 has been a pivotal and productive year for CollPlant which resulted in several significant achievements. With our unique and pioneering technology, resilient workforce and strong financial position, we have made meaningful progress in our business collaborations, products development, human assets and advancement of our strategy. I am happy to share with you the main highlights of this past year. L e t t er f r om the C E O Collaborations We opened 2021 with the exciting news about CollPlant entering into a development and commercialization agreement with Allergan Aesthetics, an AbbVie company . In this partnership, we are generating a paradigm shift in medical aesthetics by combining our recombinant human collagen technology with Allergan's proprietary technol..."
12/02/2021 6-K Quarterly results
11/18/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results Company launches rhCollagen-based BioInk platform with Collink.3D TM for use in 3D bioprinting of human tissues, scaffolds and organs"
11/15/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Announces Commercial Launch of BioInk Platform with Collink.3D TM for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs rhCollagen-based BioInk provides biopharma and academia with attractive alternative to tissue extracted collagen for use in new product development REHOVOT, Israel, November 15, 2021 /PRNewswire/ - CollPlant Biotechnologies , a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the launch of Collink.3D, a recombinant human collagen - based BioInk solution for use in 3D bioprinting. Collink.3D, CollPlant’ s first commercially available rhCollagen-based BioInk product is designed to allow the scalable and reproduceable biofabrication of scaffolds, ..."
10/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "CURRENT REPORT OF PRIVATE ISSUER",
"CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs REHOVOT, Israel, October 11 th /PRNewswire/ - CollPlant Biotechnologies , a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that its recombinant human collagen -based bioink was used successfully by researchers from Israel's Technion Institute of Technology to create a 3D bioprinted implantable tissue containing a network of blood vessels capable of supplying blood to the implanted tissue. "We are excited with the impressive and innovative work of our collaborators at the Technion,” said Yehiel Tal, CollPlant's CEO. "The combination of rhCollagen-based bioink and patie..."
09/13/2021 6-K Quarterly results
09/09/2021 6-K Quarterly results
08/19/2021 6-K Quarterly results
08/04/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER"
06/25/2021 6-K Quarterly results
06/22/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy